EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Timing of SMN replacement therapies in mouse models of spinal muscular atrophy: a systematic review and meta-analysis

Helena Chaytow iD, Anna A L Motyl iD, Yu-Ting Huang, Charis Wong iD, Gillian L Currie, Zsanett Bahor, Emily Sena iD, Thomas H Gillingwater iD

Brain Communications · 02.07.2024 · 6 (4)

DOI: 10.1093/braincomms/fcae267 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Brain Communications, online erschienen am 12.08.2024. Verfasst von Helena Chaytow und 7 weiteren Autor:innen. Beteiligte Einrichtung: Edinburgh Medical School: Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9AG, UK. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: SMA Europe and LifeArc/Chief Scientific Office Scotland, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mutations in the Survival of Motor Neuron 1 gene lead to a loss of survival motor neuron protein in patients with spinal muscular atrophy. Revolutionary advances in gene therapy have led to survival motor neuron-replacement therapies that significantly prolong life expectancy and improve neuromuscular function. However, accumulating evidence suggests that the timing of survival motor neuron-replacement therapies is a critical determinant of success. We performed a systematic review and meta-analysis of all pre-clinical studies testing survival motor neuron replacement therapies in mouse models of spinal muscular atrophy to assess the impact of timing of delivery on therapeutic effectiveness. We incorporated four databases in this pre-registered study (PROSPERO 2020 CRD42020200180): EMBASE, PubMed, Scopus and Web of Science. Inclusion criteria were; primary research article, a measure of survival analysis, use of survival motor neuron mouse model and evaluation of survival motor neuron-targeting therapy. Exclusion criteria included; use of therapies not known to directly target survival motor neuron, genetic manipulations and/or lack of appropriate controls. We screened papers using the SyRF platform. The main outcome we assessed was survival in treated groups compared to untreated groups. We performed meta-analysis of survival using median survival ratio and the random effects model and measured heterogeneity using the I2 statistic. Subgroup analyses were performed to assess treatment efficacy based on timing of intervention (embryonic delivery, day of birth, postnatal day 2 and postnatal day 3 or later) and treatment type. If detailed in the studies, body weight compared to untreated spinal muscular atrophy models and motor neuron number were included as secondary outcomes for meta-analysis. 3469 studies were initially identified, with 78 ultimately included. Survival motor neuron-replacement therapies significantly affected survival in favour of treatment by a factor of 1.20 (95% CI 1.10–1.30, P < 0.001) with high heterogeneity (I2 = 95%). Timing of treatment was a significant source of heterogeneity (P < 0.01), with earlier treatment having a greater impact on survival. When stratified by type of treatment, earlier treatment continued to have the strongest effect with viral vector replacement therapy and antisense oligonucleotide therapy. Secondary outcome measures of body weight and spinal motor neuron counts were also positively associated with early treatment. Earlier delivery of survival motor neuron replacement therapies is therefore a key determinant of treatment efficacy in spinal muscular atrophy.

Schlagwörter

Stichwörter der Autor:innen

SMAearly treatmentmeta-analysispre-clinicalsystematic review

Autor:innen und Institutionen

  • Edinburgh Medical School: Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9AG, UK.
  • Euan MacDonald Centre for Motor Neuron Disease, University of Edinburgh, Edinburgh EH16 4SB, UK.
  • Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh EH16 4SB, UK.
  • Anne Rowling Regenerative Neurology Clinic, University of Edinburgh, Edinburgh EH16 4SB, UK.
  • MRC Clinical Trials Unit, University College London, London WC1V 6LJ, UK.

ORCID-Profile: Helena Chaytow, Anna A L Motyl, Charis Wong, Emily Sena, Thomas H Gillingwater

Förderung

  • SMA Europe and LifeArc/Chief Scientific Office Scotland
  • Medical Research Council

Zitieren

APA

Chaytow, H., Motyl, A. A. L., Huang, Y. T., Wong, C., Currie, G. L., Bahor, Z., Sena, E., & Gillingwater, T. H. (2024). Timing of SMN replacement therapies in mouse models of spinal muscular atrophy: a systematic review and meta-analysis. Brain Communications, 6(4). https://doi.org/10.1093/braincomms/fcae267

Vancouver

Chaytow H, Motyl AAL, Huang YT, Wong C, Currie GL, Bahor Z, et al. Timing of SMN replacement therapies in mouse models of spinal muscular atrophy: a systematic review and meta-analysis. Brain Communications. 2024;6(4). doi:10.1093/braincomms/fcae267

BibTeX
@article{Chaytow2024,
  author = {Chaytow, Helena and Motyl, Anna A L and Huang, Yu-Ting and Wong, Charis and Currie, Gillian L and Bahor, Zsanett and Sena, Emily and Gillingwater, Thomas H},
  title = {Timing of SMN replacement therapies in mouse models of spinal muscular atrophy: a systematic review and meta-analysis},
  journal = {Brain Communications},
  year = {2024},
  volume = {6},
  number = {4},
  doi = {10.1093/braincomms/fcae267}
}
Kostenlos starten →